OJEMDATM (tovorafenib) has been approved in the United States by the Food and Drug Administration for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
OJEMDA is no longer available for expanded access or compassionate use in the United States.
OJEMDA may be available to patients outside of the United States contingent upon meeting eligibility criteria and subject, in certain circumstances, to receiving local regulatory approval. To receive more information about access to tovorafenib outside the United States please contact [email protected]
For medical inquiries in the U.S., please email [email protected]
